HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

MRA monoclonal antibody

is a humanized anti-interleukin-6 receptor monoclonal antibody being developed by Chugai, the Japanese subsidiary of Roche, for the potential treatment of multiple myeloma, rheumatoid arthritis, and Crohn disease. It is now in Phase II clinical trials.
Also Known As:
monoclonal antibody, MRA
Networked: 2 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Imagawa, Tomoyuki: 1 article (03/2005)
2. Yokota, Shumpei: 1 article (03/2005)
3. Yoshizaki, Kazuyuki: 1 article (03/2005)
4. Miyamae, Takako: 1 article (03/2005)
5. Nishimoto, Norihiro: 1 article (03/2005)
6. Kishimoto, Tadamitsu: 1 article (03/2005)
7. Katakura, Shigeki: 1 article (03/2005)
8. Iwata, Naomi: 1 article (03/2005)
9. Mori, Masaaki: 1 article (03/2005)
10. Woo, Patricia: 1 article (03/2005)

Related Diseases

1. Juvenile Rheumatoid Arthritis (Juvenile Idiopathic Arthritis)
2. Multiple Myeloma
3. Crohn Disease (Crohn's Disease)
4. Rheumatoid Arthritis

Related Drugs and Biologics

1. Interleukin-6 (Interleukin 6)
2. Adrenal Cortex Hormones (Corticosteroids)
3. Interleukins